By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
Panelists agree that Truist's PT cut signals materializing competitive threats to BRINSUPRI, with concerns about sustaining demand post the initial patient boost and achieving the $1B 2026 target.
Risk: Loss of pricing power, payer rebate pressure, and potential erosion of 90% approval rates due to competitive threats.
Opportunity: None explicitly stated.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
With a 5-year average revenue growth rate of 23.8%, Insmed Incorporated (NASDAQ:INSM) is included among the 11 Best Long Term US Stocks to Buy Right Now.
On May 13, Truist lowered the firm’s price target on Insmed Incorporated (NASDAQ:INSM) to $185 from $205 while maintaining a Buy rating on the shares. The analyst said the firm updated its model following Q1 results, taking into account recent competitive developments and adjusting Brinsupri estimates based on physician feedback gathered after earnings.
During the Q1 2026 earnings call, President, CEO, and Chairman William Lewis said BRINSUPRI, the company’s once-daily oral reversible inhibitor of dipeptidyl peptidase 1 (DPPI), delivered 44% sequential growth. He added that management remained confident in its 2026 revenue outlook of at least $1 billion. Lewis also said the company did not raise the price of BRINSUPRI at the start of 2026 and noted that the impact from inventory stocking during the quarter was minimal.
Discussing demand trends, Lewis estimated that about 1,500 of the nearly 7,800 new patients who started treatment during the quarter came from the company’s “ready and waiting” patient group. He added that management believed the boost tied to those patients had mostly played out as the company moved into the second quarter. Lewis also pointed to positive trends in patient access and adherence. He said the approval rate since launch had been close to 90% and noted that more than 80% of patients using BRINSUPRI had joined the company’s inLighten patient support program.
Insmed Incorporated (NASDAQ:INSM) is a global biopharmaceutical company focused on developing approved and investigational medicines, along with advancing drug discovery programs.
While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 11 Best Dividend Penny Stocks to Buy Right Now and 10 Best “Dogs of the Dow” Stocks to Buy for the Rest of 2026
Disclosure: None. Follow Insider Monkey on Google News.
Four leading AI models discuss this article
"The PT reduction highlights real competitive risks that could derail the $1B revenue goal once the initial patient bolus is exhausted."
Truist's PT cut on INSM to $185 signals that competitive threats to BRINSUPRI are materializing faster than prior models assumed, even as the firm keeps its Buy rating. The Q1 call highlighted a one-time lift from 1,500 ready-and-waiting patients, 90% approval rates, and flat pricing, yet management offered little new detail on how sustained demand will hold once that bolus fades in Q2. With 23.8% historical revenue growth now facing DPP1 rivals, the $1B 2026 target looks increasingly back-loaded and vulnerable to share loss. Second-order risks include slower adherence trends and potential reimbursement pushback not addressed in the earnings remarks.
If physician feedback proves overly cautious and BRINSUPRI's convenience edge drives faster switching than expected, the lowered target could be revised upward within two quarters, restoring momentum toward prior levels.
"Management's admission that the largest source of Q1 patient growth is exhausted by Q2 signals the market is pricing in higher growth than the company itself now expects."
Truist's $20 PT cut (9.8% downside) on maintained Buy is a yellow flag disguised as a hold. The real story: BRINSUPRI's 44% sequential growth masks a deceleration narrative. Management explicitly flagged that the 'ready and waiting' patient boost—1,500 of 7,800 Q1 starts—is 'mostly played out' by Q2. That's ~19% of Q1 patient additions evaporating. Combined with no price increases and competitive pressure Truist won't detail, the $1B 2026 revenue target looks increasingly optimistic. The 23.8% 5-year CAGR is backward-looking; forward growth is the question.
INSM could still hit $1B revenue and expand margins if BRINSUPRI penetration accelerates beyond the 'ready and waiting' cohort, and the 90% approval rate suggests genuine demand, not just inventory pull-forward.
"The exhaustion of the 'ready and waiting' patient pool shifts the investment thesis from momentum-based growth to the sustainability of organic, competitive market share acquisition."
Truist’s price target cut to $185 is a classic 'sell the news' signal on a high-growth biotech. While 44% sequential growth for BRINSUPRI is impressive, the admission that the 1,500 'ready and waiting' patient bolus has exhausted itself is the real story. Insmed is now entering a 'show me' phase where organic, non-bolus prescription growth must sustain the $1 billion revenue guidance. At a 23.8% five-year revenue CAGR, the valuation is priced for perfection. If the competitive landscape—likely from emerging DPPI inhibitors—starts to erode that 90% approval rate, the current premium multiple will contract rapidly. Investors should watch the Q2 launch velocity closely to see if the growth curve flattens.
If Insmed’s 90% approval rate and 80% patient support program enrollment reflect a durable 'moat' rather than just early-adopter enthusiasm, the stock could easily re-rate higher once the market realizes the competitive threat is overstated.
"Sustained BRINSUPRI uptake and favorable payer dynamics are the key unlocks; any slowdown or price/competition pressure could derail the anticipated revenue trajectory."
Truist’s cut to $185 from $205 signals growing concern around BRINSUPRI’s competitive landscape and near-term uptake. The Q1 sequential 44% growth looks strong, but the ‘ready and waiting’ patient bolt-on (~1.5k of 7.8k) may imply limited upside beyond the initial wave, with expectations for Q2 normalization. The lack of a price increase in 2026 and modest inventory impact are positives, yet the 2026 revenue target of at least $1B seems ambitious if addressable patient pools don’t expand or payer constraints tighten. Missing context includes who the competitive developments are, and how reimbursement progresses across geographies.
The upside could be front-loaded and hinge on one-off patient uptake; if competitive pressure intensifies or payer coverage stalls, the $1B target may prove unsustainable long-term.
"Flat pricing combined with fading bolus leaves BRINSUPRI exposed to reimbursement pressures and competitive share loss."
ChatGPT overlooks how the absence of pricing power amplifies the bolus fade risk beyond Q2. With the 1,500 ready-and-waiting patients mostly exhausted and no price increases slated for 2026, sustained 90% approval rates may fail to counter DPP1 rivals if payers push for rebates. This directly threatens the $1B revenue target, leaving minimal cushion against volume slowdowns or adherence drops that remain unaddressed.
"The bolus fade is real, but the math doesn't yet prove the $1B target is at risk if baseline growth holds mid-20s."
Grok flags payer rebate pressure, but that's speculative without evidence from the earnings call or Truist's report. The real blind spot: nobody quantified what 'mostly played out' means for Q2 patient additions. If 1,500 of 7,800 Q1 starts was 19% of volume, and that repeats in Q2, we're looking at ~6,300 starts—still 43% sequential growth. That's not collapse; it's normalization. The $1B target survives unless organic (non-bolus) growth turns negative, which hasn't been demonstrated.
"The transition from bolus-driven growth to organic growth will likely trigger margin compression due to higher customer acquisition costs."
Claude, your math on normalization assumes a static market, but you're ignoring the 'second-order' risk: the cost of acquisition. If Insmed must spend more on marketing and patient support to maintain those 6,300 starts now that the low-hanging 'ready-and-waiting' fruit is gone, margins will compress even if revenue holds. We aren't just looking at volume; we are looking at the efficiency of that volume. If CAC (customer acquisition cost) rises, the $1B revenue target becomes a hollow victory.
"CAC-driven margin risk could derail the $1B 2026 target even with revenue growth"
Gemini, the CAC angle is real but unaddressed: to sustain 6,300 starts in Q2 and beyond, Insmed may need heavier marketing and patient support spend, which could erode margins even if revenue grows. If the company can't improve per-patient cost efficiency or secure rebates to keep net pricing stable, the $1B 2026 target risks margin pressure and a lower multiple, independent of demand.
Panelists agree that Truist's PT cut signals materializing competitive threats to BRINSUPRI, with concerns about sustaining demand post the initial patient boost and achieving the $1B 2026 target.
None explicitly stated.
Loss of pricing power, payer rebate pressure, and potential erosion of 90% approval rates due to competitive threats.